What is he best known for?
The fields of study he is best known for:
- Gene
- Antibody
- Immune system
Immunology, B cell, Lupus erythematosus, Germinal center and Autoantibody are his primary areas of study.
His Immunology study frequently draws connections between related disciplines such as Naive B cell.
His B cell study results in a more complete grasp of Antibody.
His Antibody study combines topics from a wide range of disciplines, such as Molecular biology, Gene and Antigen.
In his study, which falls under the umbrella issue of Lupus erythematosus, Anti-SSA/Ro autoantibodies, Rheumatoid arthritis, Effector and B-cell activating factor is strongly linked to Pathogenesis.
His Polyreactive antibodies study, which is part of a larger body of work in Autoantibody, is frequently linked to Repertoire, bridging the gap between disciplines.
His most cited work include:
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab (693 citations)
- Rituximab Improves Peripheral B Cell Abnormalities in Human Systemic Lupus Erythematosus (400 citations)
- The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus (388 citations)
What are the main themes of his work throughout his whole career to date?
Iñaki Sanz spends much of his time researching Immunology, B cell, Antibody, Autoantibody and Rituximab.
His research is interdisciplinary, bridging the disciplines of Internal medicine and Immunology.
His B cell research is multidisciplinary, relying on both Phenotype, Cell biology, CD19 and B-1 cell.
His Antibody study integrates concerns from other disciplines, such as Molecular biology, Lymphocyte and Antigen.
He combines subjects such as Systemic lupus erythematosus and Somatic hypermutation with his study of Autoantibody.
Iñaki Sanz has included themes like Therapeutic approach, Disease, Clinical trial, Monoclonal and Rheumatoid arthritis in his Rituximab study.
He most often published in these fields:
- Immunology (60.40%)
- B cell (39.60%)
- Antibody (33.66%)
What were the highlights of his more recent work (between 2016-2020)?
- B cell (39.60%)
- Immunology (60.40%)
- Antibody (33.66%)
In recent papers he was focusing on the following fields of study:
Iñaki Sanz mostly deals with B cell, Immunology, Antibody, Autoantibody and Computational biology.
His B cell study combines topics in areas such as Autoimmune disease, Multiplex, Epigenetics and Immune tolerance.
The concepts of his Immunology study are interwoven with issues in Systemic lupus erythematosus and Cell survival.
His biological study spans a wide range of topics, including Convalescence and Immunity.
His work deals with themes such as Phenotype, Disease and Transplant rejection, which intersect with Autoantibody.
His Computational biology research integrates issues from breakpoint cluster region and Antigen.
Between 2016 and 2020, his most popular works were:
- Epigenetic programming underpins B cell dysfunction in human SLE (44 citations)
- Factors of the bone marrow microniche that support human plasma cell survival and immunoglobulin secretion (36 citations)
- BALDR: a computational pipeline for paired heavy and light chain immunoglobulin reconstruction in single-cell RNA-seq data (30 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Antibody
- Immune system
Iñaki Sanz focuses on B cell, Cell biology, Computational biology, Antibody and Antigen.
The various areas that Iñaki Sanz examines in his B cell study include Lupus erythematosus, Epigenesis, Epigenetics and Effector.
His Cell biology study incorporates themes from Transcriptome, Downregulation and upregulation and Bone marrow.
His Transcriptome research includes themes of Chromatin, Immunoglobulin secretion, In vitro and Epigenome.
His studies in Computational biology integrate themes in fields like Phenotype, Autoantibody, Disease and Transplant rejection.
His research in Antibody intersects with topics in breakpoint cluster region and Simian immunodeficiency virus.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
